Cancer Risk in ATM Heterozygotes: A Model of Phenotypic and Mechanistic Differences between Missense and Truncating Mutations
- 31 December 1999
- journal article
- review article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 68 (4), 419-423
- https://doi.org/10.1006/mgme.1999.2942
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A Model for ATM Heterozygote Identification in a Large Population: Four Founder-Effect ATM Mutations Identify Most of Costa Rican Patients with Ataxia TelangiectasiaMolecular Genetics and Metabolism, 1998
- ATM Mutations and Phenotypes in Ataxia-Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast CancerAmerican Journal of Human Genetics, 1998
- Biallelic mutations in the ATM gene in T-prolymphocytic leukemiaNature Medicine, 1997
- Heterozygous ATM mutations do not contribute to early onset of breast cancerNature Genetics, 1997
- AT-tributable risks?Nature Genetics, 1997
- Diversity ofATM gene mutations detected in patients with ataxia-telangiectasiaHuman Mutation, 1997
- Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancerCancer Genetics and Cytogenetics, 1996
- Predominance of null mutations in ataxia-telangiectasiaHuman Molecular Genetics, 1996
- A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 KinaseScience, 1995
- Incidence of Cancer in 161 Families Affected by Ataxia–TelangiectasiaNew England Journal of Medicine, 1991